Chagas disease

  title={Chagas disease},
  author={Jos{\'e} Antonio P{\'e}rez-Molina and Israel Molina},
  journal={The Lancet},
Chagas disease is an anthropozoonosis from the American continent that has spread from its original boundaries through migration. It is caused by the protozoan Trypanosoma cruzi, which was identified in the first decade of the 20th century. Once acute infection resolves, patients can develop chronic disease, which in up to 30-40% of cases is characterised by cardiomyopathy, arrhythmias, megaviscera, and, more rarely, polyneuropathy and stroke. Even after more than a century, many challenges… Expand
Trypanocidal treatment of Chagas disease.
This review focuses on the aspects that allow clinicians to make the best use of currently available drugs for chagas disease, and discusses new therapeutic options and ongoing research in the field. Expand
Drug discovery for chagas disease : A viewpoint Jadel
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi. It is a significant public health problem, affecting millions of people worldwide. And although itExpand
Chapter 2 Chagas Disease in the Yucatan Peninsula , Mexico
American trypanosomiasis or Chagas disease is caused by the protozoan Trypanosoma cruzi, which affects a wide variety of hosts including the man, until now treatment options or vaccines developed areExpand
WHF IASC Roadmap on Chagas Disease
The WHF IASC Roadmap proposes strategies and evidence-based solutions for healthcare professionals, health authorities and governments to help overcome the barriers to comprehensive care for Chagas disease patients. Expand
Orbital Cellulitis in Chagas Disease: An Unusual Presentation.
A case of a 47-year-old healthy farmer diagnosed with a right orbital cellulitis refractory to systemic antibiotics, who had a proper recovery and continued with a regular follow-up to monitor the possible development of a chronic phase of Chagas disease. Expand
Current trends in the pharmacological management of Chagas disease
It was possible to conclude that the use of benznidazole in combination with other compounds showed better results when compared with its use as a single therapy. Expand
Trypanosoma cruzi infection associated with atypical clinical manifestation during the acute phase of the Chagas disease
A case of CD with disseminated skin lesions that was detected by PCR and showed negative serological results is presented, which demonstrates the ability of the parasite to initiate and maintain infections in atypical tissues. Expand
Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
Posaconazole was clearly superior in treatment of acute disease whereas only benznidazole had efficacy in the chronic model, and these results have important implications for the design and analysis of human clinical trials, and the use of specific drugs in specific clinical settings. Expand
Nano-Medicines a Hope for Chagas Disease!
An insight is provided into the life cycle stages of the pathogen in both vertebrate host and the insect vector, along with an overview of the current therapy for Chagas disease and its limitations; nano carrier-based delivery systems for antichagasic agents, and the advancement of nano vaccines and nano-diagnostic techniques are addressed. Expand
Autochthonous Chagas Disease in the United States: How Are People Getting Infected?
In the United States, Chagas disease is diagnosed in less than 1% of the estimated > 300,000 people who have the disease. However, the actual prevalence remains unknown, and these estimates may beExpand